中文 | English



Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners



Lingmed Newsletter Nov 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Innovative type 2 diabetes sustained-release project from US
  • Lingmed asset recommendation 2：Migraine Inhalation Project from EU
  • The Oct 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Oct 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed Newsletter Oct 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Innovative oral preparation project for Age-related Macular Degeneration
  • Lingmed asset recommendation 2：Innovative respiratory disease project from EU
  • Lingmed monthly webinar Nov 2023: Research progress in the pathogenesis and treatment of depression
  • The Sep 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Sep 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed Newsletter Sep 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Long-acting Pulmonary Arterial Hypertension Program from EU
  • Lingmed asset recommendation 2：Long-acting Preloaded Prostate Cancer program from EU
  • Lingmed monthly webinar Oct 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
  • The Aug 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Aug 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed asset recommendation No.344

European Long-Term Pulmonary Arterial Hypertension Program seeks global partnering

  • Global and China Pulmonary Hypertension Epidemiology
  • Global Pulmonary Arterial Hypertension Drug Ranking
  • Treatment of Pulmonary Arterial Hypertension in China
  • Lingmed innovative asset recommendation –Pulmonary Arterial Hypertension

Lingmed asset recommendation No.343

European Long-acting Preloaded Prostate Cancer program seeks global partnering - LMP1855

  • Global and China Prostate Cancer Epidemiology
  • Global Prostate Cancer Drug Ranking
  • Treatment of Prostate Cancer in China
  • Lingmed innovative asset recommendation – Prostate Cancer program

Lingmed Newsletter Aug 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria
  • Lingmed asset recommendation 2：Innovative Chronic Kidney Disease program
  • Lingmed monthly webinar Sep 2023: Breakthrough & Progress of Non-small cell lung cancer drug Register
  • The 12th Pharma - Biotech Product and Company Valuation Register
  • The July 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The July 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed asset recommendation No.341

Innovative Chronic Kidney Disease program seeks a global partner

  • Global and China Chronic Kidney Disease Epidemiology
  • Global Chronic Kidney Disease Drug Ranking
  • Treatment of Chronic Kidney Disease in China
  • Lingmed innovative asset recommendation – Chronic Kidney Disease project

Lingmed asset recommendation No.340

Spot light on dermatology innovation - Cure for chronic Spontaneous Urticaria?

  • Global and Chinese Epidemiology of Chronic Spontaneous Urticaria
  • Global and Chinese Urticaria Drug Ranking
  • Treatment of Chronic Spontaneous Urticaria in China
  • Lingmed innovative asset recommendation – Chronic Spontaneous Urticaria Program

Lingmed asset recommendation No.338

China's rising stars of innovation - portable inhalation device for pulmonary hypertension - Patent global licensing opportunity LMP1853

  • Medical NO gas therapy has wide application potential
  • Integrating more than 60 patents to establish a solid NO generation molecular technology platform
  • Potential indications and product forms
  • Portable nitric oxide inhalation therapy device
  • Product features
  • The main uses of the LMP1853 portable inhaled nitric oxide therapy device
  • Cooperation models

Lingmed Newsletter July 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Innovative U.S. Anesthesia Reversal Agent program
  • Lingmed asset recommendation 2：Oversea topical skin disease innovation
  • Lingmed monthly webinar Aug 2023: Development progress of new drug development for skin diseases Register
  • The 12th Pharma - Biotech Product and Company Valuation Register
  • The Jun 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Jun 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed asset recommendation No.336

Oversea topical skin disease innovations

  • Global and Chinese Acne Epidemiology
  • Global and Chinese Acne Drug List
  • Chinese acne treatment
  • Lingmed innovative asset recommendation – Skin Disease Program

Lingmed asset recommendation No.336

Innovative U.S. Anesthesia Reversal Agent program seeks partnering into China market

  • Global Epidemiology of Delayed Awakening from Anesthesia
  • Global & Chinese Delayed Awakening from Anesthesia Drug Ranking
  • Chinese Guidelines for Treatment of Delayed Awakening from Anesthesia
  • Lingmed innovative asset recommendation – Anesthesia Reversal Agent Program

Lingmed Newsletter June 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：New breakthrough in innovative target for rare blood diseases
  • Lingmed asset recommendation 2：Overseas Primary Sclerosing Cholangitis program
  • Lingmed monthly webinar Jul 2023: Chronic Pain Market Development Potential and Market Size   Register
  • The 12th Pharma - Biotech Product and Company Valuation   Register
  • The May 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The May 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed asset recommendation No.334

Overseas primary sclerosing cholangitis program seeks partnering into China market

  • Global and Chinese PSC Epidemiology
  • Global & Chinese PSC Drug Ranking
  • Chinese guidelines for diagnosis and treatment of PSC
  • Lingmed innovative asset recommendation – Primary Sclerosing Cholangitis Program

Lingmed asset recommendation No.333

New breakthrough in innovative target for rare blood diseases - LMP1421

  • Global PNH Epidemiology
  • Global & Chinese PNH Drug Ranking
  • Chinese guidelines for diagnosis and treatment of PNH
  • Lingmed innovative asset recommendation – PHN Program

Lingmed Newsletter May 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Overseas First-Line Therapy Program for Pancreatic Cancer
  • Lingmed asset recommendation 2：U.S. Innovative Oncology Program
  • Lingmed monthly webinar Jun 2023: Prospects for drug development of heterologous antibodies  Register
  • The Apr 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Apr 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed asset recommendation No.331

Oncology innovation from US biotech seeks partnering into China market

  • Global epidemiology of AML/ALL, DLBCL, MM and other tumors
  • Global & Chinese AML/ALL Drug Ranking
  • China AML/ALL diagnosis and treatment guidelines
  • Lingmed innovative asset recommendation – Multi-tumor Indication Program

Lingmed asset recommendation No.328

Overseas First-Line Therapy Program for Pancreatic Cancer Seeks Chinese Collaboration

  • Global & Chinese Pancreatic Cancer Epidemiology
  • Global Pancreatic Cancer Drug Ranking
  • China Pancreatic Cancer Treatment Guidelines (2022)
  • Lingmed innovative asset recommendation – Pancreatic Cancer and Pulmonary Fibrosis Program

Lingmed Newsletter April 2023

In this month summary, Lingmed recommends

  • Lingmed asset recommendation 1：Phase III Tenosynovial Giant Cell Tumor Program from EU
  • Lingmed asset recommendation 2：U.S. Innovative Respiratory Infection Program
  • Lingmed monthly webinar May 2023: R&D pattern analysis of novel drug delivery systems Register
  • The Mar 2023 Overview of cross-border pharmaceutical BD deals in China by Lingmed analysis team
  • The Mar 2023 Financial analysis of global biopharmaceuticals market by Biotechgate data analysis team

Lingmed asset recommendation No.329

U.S. Innovative Respiratory Infection Program Seeks Chinese Collaboration

  • Company Profile
  • Respiratory Infection Program LMP1857 Introduction
  • LMP1857 potential applications
  • LMP1857 patent status
  • LMP1857 Cooperation Opportunities

Lingmed asset recommendation No.327

European Phase III Tenosynovial Giant Cell Tumor Program Seeks Chinese Collaboration

  • Global & Chinese Epidemiology of Tenosynovial Giant Cell Tumor
  • Global Tenosynovial Giant Cell Tumor Drug Ranking
  • Guidelines for Diagnosis and Treatment of Giant Cell Tumor of the Tendon Sheath in China
  • Lingmed innovative asset recommendation – Tenosynovial giant cell tumor program



If you are interested in Lingmed historical achieved reports, please click here




Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *
Notes

Download Report
©Copyright 2013 - Lingmed Limited